<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of hypercalcemia</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of hypercalcemia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of hypercalcemia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth Shane, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James R Berenson, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Clifford J Rosen, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jean E Mulder, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 05, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Treatment for hypercalcemia should be aimed both at lowering the serum calcium concentration and, if possible, treating the underlying disease. Effective treatments reduce serum calcium by inhibiting bone resorption, increasing urinary calcium excretion, or decreasing intestinal calcium absorption  (<a class="graphic graphic_table graphicRef73030" href="/d/graphic/73030.html" rel="external">table 1</a>). The optimal choice varies with the cause and severity of hypercalcemia.</p><p>The treatment of hypercalcemia will be reviewed here, with emphasis on the management of hypercalcemia in patients with malignant disease. The modalities described below apply in varying degrees to patients with other causes of hypercalcemia. The clinical manifestations, etiology, and diagnostic approach to hypercalcemia are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/832.html" rel="external">"Clinical manifestations of hypercalcemia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/839.html" rel="external">"Etiology of hypercalcemia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/836.html" rel="external">"Diagnostic approach to hypercalcemia"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">INTERPRETATION OF SERUM CALCIUM</span><span class="headingEndMark"> — </span>Calcium in serum is bound to proteins, principally albumin. As a result, total serum calcium concentrations in patients with low or high serum albumin levels may not accurately reflect the physiologically important ionized (or free) calcium concentration. As an example, in patients with hypoalbuminemia, total serum calcium concentration may be normal when serum ionized calcium is elevated.</p><p>Alternatively, patients with hyperalbuminemia due to severe volume depletion and rare patients with multiple myeloma, who have a calcium-binding paraprotein, have increased protein binding of calcium. This can cause an elevation in the serum total calcium concentration without any rise in the serum ionized calcium concentration. This phenomenon is called pseudohypercalcemia (or factitious hypercalcemia) since the patient has a normal ionized serum calcium concentration.</p><p>In patients with hypoalbuminemia or hyperalbuminemia, the measured serum calcium concentration should be corrected for the abnormality in albumin (<a class="calc calc_professional" href="/d/html/13477.html" rel="external">calculator 1</a>) or for standard units (<a class="calc calc_professional" href="/d/html/13475.html" rel="external">calculator 2</a>). If a laboratory known to measure ionized calcium reliably is available, some authorities prefer to measure the serum ionized calcium in this situation. (See  <a class="medical medical_review" href="/d/html/845.html" rel="external">"Relation between total and ionized serum calcium concentrations"</a>.)</p><p class="headingAnchor" id="H1248397"><span class="h1">PREFERRED APPROACH</span><span class="headingEndMark"> — </span>Hypercalcemia may be associated with a spectrum of clinical manifestations, ranging from few or no symptoms in patients with mild chronic hypercalcemia to severe obtundation and coma (see  <a class="medical medical_review" href="/d/html/832.html" rel="external">"Clinical manifestations of hypercalcemia"</a>). The degree of hypercalcemia, along with the rate of rise of serum calcium concentration, often determines symptoms and the urgency of therapy. The therapeutic approach should reflect these differences [<a href="#rid1">1-3</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with asymptomatic or mildly symptomatic (eg, constipation) hypercalcemia (calcium &lt;12 mg/dL [3 mmol/L]) do not require immediate treatment. (See <a class="local">'Mild hypercalcemia'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with a serum calcium of 12 to 14 mg/dL (3 to 3.5 mmol/L) may not require immediate treatment, because that degree of hypercalcemia may be well tolerated chronically (see <a class="local">'Moderate hypercalcemia'</a> below). However, an acute rise to these concentrations may cause marked changes in sensorium, which requires more aggressive measures. (See <a class="local">'Severe hypercalcemia'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with a serum calcium concentration &gt;14 mg/dL (3.5 mmol/L) require more aggressive treatment, regardless of symptoms. (See <a class="local">'Severe hypercalcemia'</a> below.)</p><p></p><p>The reference range for ionized calcium varies with the assay, and therefore, the ionized calcium thresholds for intervention depend on the assay. In an ionized calcium assay with a normal range of 4.8 to 5.6 mg/dL (1.2 to 1.4 mmol/L), mild, moderate, and severe hypercalcemia may be defined as follows [<a href="#rid4">4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Mild – Ionized calcium 5.6 to 8 mg/dL (1.4 to 2 mmol/L)</p><p class="bulletIndent1"><span class="glyph">●</span>Moderate – Ionized calcium 8 to 10 mg/dL (2 to 2.5 mmol/L)</p><p class="bulletIndent1"><span class="glyph">●</span>Severe – Ionized calcium 10 to 12 mg/dL (2.5 to 3 mmol/L)</p><p></p><p class="headingAnchor" id="H1248476"><span class="h1">MILD HYPERCALCEMIA</span><span class="headingEndMark"> — </span>Patients with asymptomatic or mildly symptomatic hypercalcemia (total albumin-corrected calcium &lt;12 mg/dL [&lt;3 mmol/L]) do not require immediate treatment. However, they should be advised to <strong>avoid</strong> factors that can aggravate hypercalcemia, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Thiazide diuretics</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">Lithium</a> carbonate</p><p class="bulletIndent1"><span class="glyph">●</span>Volume depletion</p><p class="bulletIndent1"><span class="glyph">●</span>Prolonged bed rest or inactivity</p><p class="bulletIndent1"><span class="glyph">●</span>A high-calcium diet (&gt;1000 mg/day)</p><p class="bulletIndent1"><span class="glyph">●</span>Calcium supplements</p><p class="bulletIndent1"><span class="glyph">●</span>Vitamin D supplements in excess of 800 international units/day</p><p class="bulletIndent1"><span class="glyph">●</span>Multivitamins containing calcium</p><p></p><p>Adequate hydration (at least six to eight glasses of water per day) is recommended to minimize the risk of nephrolithiasis. Additional therapy depends mostly upon the cause of the hypercalcemia. (See <a class="local">'Disease-specific approach'</a> below.)</p><p class="headingAnchor" id="H1248482"><span class="h1">MODERATE HYPERCALCEMIA</span><span class="headingEndMark"> — </span>Asymptomatic or mildly symptomatic individuals with chronic moderate hypercalcemia (total albumin-corrected calcium between 12 and 14 mg/dL [3 to 3.5 mmol/L]) may not require immediate therapy. However, they should follow the same precautions described above for mild hypercalcemia.</p><p>It is important to note that an acute rise to these concentrations may cause marked changes in sensorium, which requires more aggressive therapy. In these patients, we typically treat with <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> hydration and bisphosphonates, as described for severe hypercalcemia. (See <a class="local">'Severe hypercalcemia'</a> below.)</p><p class="headingAnchor" id="H1248513"><span class="h1">SEVERE HYPERCALCEMIA</span><span class="headingEndMark"> — </span>Patients with total albumin-corrected calcium &gt;14 mg/dL (&gt;3.5 mmol/L) require more aggressive therapy. As described immediately above, patients with an acute rise in serum calcium to more moderate levels who have changes in sensorium (eg, lethargy, stupor) also require aggressive therapy.</p><p>Initial therapy of severe hypercalcemia includes the simultaneous administration of intravenous (IV) isotonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>, subcutaneous <a class="drug drug_general" data-topicid="9182" href="/d/drug information/9182.html" rel="external">calcitonin</a>, and a bisphosphonate (typically, IV <a class="drug drug_general" data-topicid="9902" href="/d/drug information/9902.html" rel="external">zoledronic acid</a>)  (<a class="graphic graphic_table graphicRef73030" data-inline-graphics="73030" href="/d/graphic/73030.html" rel="external">table 1</a>) [<a href="#rid1">1,2,5</a>]. The administration of calcitonin plus saline hydration should result in substantial reduction in serum calcium concentrations within 12 to 48 hours. The bisphosphonate will be effective by the second to fourth day and provide a more sustained effect, thereby maintaining control of the hypercalcemia.</p><p class="headingAnchor" id="H1453985307"><span class="h2">Volume expansion with isotonic saline</span><span class="headingEndMark"> — </span>Most patients presenting with severe hypercalcemia have marked intravascular volume depletion. Hypovolemia exacerbates hypercalcemia by impairing the renal clearance of calcium [<a href="#rid6">6</a>]. Isotonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> for 24 to 48 hours corrects possible volume depletion due to hypercalcemia-induced urinary salt wasting and, in some cases, vomiting [<a href="#rid7">7,8</a>].</p><p>The rate of <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> infusion depends upon several factors, including the severity of hypercalcemia, the age of the patient, and presence of comorbid conditions, particularly underlying cardiac or renal disease. A reasonable regimen, in the absence of edema, is the administration of isotonic saline at an initial rate of 200 to 300 mL/hour that is then adjusted to maintain the urine output at 100 to 150 mL/hour.</p><p>In the absence of renal failure or heart failure, loop diuretic therapy to directly increase calcium excretion is not recommended [<a href="#rid9">9</a>], because of the availability of drugs (eg, bisphosphonates) that inhibit bone resorption, which is primarily responsible for the hypercalcemia, as well as the potential for fluid and electrolyte complications (eg, hypokalemia, hypomagnesemia) and volume depletion resulting from a massive <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> infusion and furosemide-induced diuresis.</p><p>However, <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> therapy can lead to fluid overload in patients who cannot excrete the administered salt because of impaired renal function or heart failure. In individuals with renal insufficiency or heart failure, careful monitoring and judicious use of loop diuretics (after intravascular volume has been repleted) may be required to prevent fluid overload.</p><p><a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">Saline</a> therapy rarely normalizes the serum calcium concentration in patients with more than mild hypercalcemia [<a href="#rid6">6</a>]. Concurrent treatment with bisphosphonates with or without <a class="drug drug_general" data-topicid="9182" href="/d/drug information/9182.html" rel="external">calcitonin</a> is typically required to treat moderate to severe hypercalcemia.</p><p class="headingAnchor" id="H4140282296"><span class="h2">Calcitonin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9182" href="/d/drug information/9182.html" rel="external">Calcitonin</a> should be administered intramuscularly or subcutaneously; nasal administration of calcitonin is not efficacious for treatment of hypercalcemia [<a href="#rid10">10</a>]. The initial dose is 4 units/kg. The serum calcium is repeated in four to six hours. If a hypocalcemic response is noted, then the patient is calcitonin sensitive and the calcitonin can be repeated every 12 hours for a total duration of 24 to 48 hours. If the response is not satisfactory, the dose may be increased to 8 units/kg every 6 to 12 hours (total duration of therapy 24 to 48 hours)  (<a class="graphic graphic_table graphicRef73030" href="/d/graphic/73030.html" rel="external">table 1</a>).</p><p>The efficacy of <a class="drug drug_general" data-topicid="9182" href="/d/drug information/9182.html" rel="external">calcitonin</a> is limited to the first 48 hours, even with repeated doses, indicating the development of tachyphylaxis, perhaps due to receptor downregulation [<a href="#rid1">1,11-13</a>]. Because of its limited duration of effect, calcitonin is most useful in symptomatic patients with calcium &gt;14 mg/dL (3.5 mmol/L), when combined with hydration and bisphosphonates (or <a class="drug drug_general" data-topicid="15575" href="/d/drug information/15575.html" rel="external">denosumab</a>, in bisphosphonate-refractory patients).</p><p>Pharmacologic doses of <a class="drug drug_general" data-topicid="9182" href="/d/drug information/9182.html" rel="external">calcitonin</a> reduce the serum calcium concentration by increasing renal calcium excretion and, more importantly, by decreasing bone resorption via interference with osteoclast function [<a href="#rid11">11,14</a>]. Calcitonin is safe and relatively nontoxic (other than mild nausea and the rare hypersensitivity reaction). Although a relatively weak agent, it works rapidly, lowering the serum calcium concentration by a maximum of 1 to 2 mg/dL (0.3 to 0.5 mmol/L) beginning within four to six hours [<a href="#rid1">1,5,15,16</a>]. Thus, it is useful in combination with hydration for the initial management of severe hypercalcemia.</p><p class="headingAnchor" id="H2069216252"><span class="h2">Choice of antiresorptive agent: Bisphosphonates</span><span class="headingEndMark"> — </span>For longer-term control of hypercalcemia in patients with more severe (calcium &gt;14 mg/dL) or symptomatic hypercalcemia due to excessive bone resorption, we suggest the addition of an IV bisphosphonate rather than <a class="drug drug_general" data-topicid="15575" href="/d/drug information/15575.html" rel="external">denosumab</a>. Bisphosphonates are relatively inexpensive, nontoxic compounds with a long track record of safety and efficacy for the treatment of hypercalcemia. They are usually the preferred agents for management of hypercalcemia due to excessive bone resorption from a variety of causes, including malignancy-related hypercalcemia [<a href="#rid17">17</a>]. Their maximum effect occurs in two to four days, so that they are usually given in conjunction with <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> and/or <a class="drug drug_general" data-topicid="9182" href="/d/drug information/9182.html" rel="external">calcitonin</a>, which reduce calcium concentration more rapidly  (<a class="graphic graphic_table graphicRef73030" href="/d/graphic/73030.html" rel="external">table 1</a>).</p><p>Randomized trials show evidence of bisphosphonate efficacy compared with <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> alone for the treatment hypercalcemia of malignancy [<a href="#rid18">18-22</a>]. There are no randomized trials specifically evaluating <a class="drug drug_general" data-topicid="15575" href="/d/drug information/15575.html" rel="external">denosumab</a> for hypercalcemia of malignancy. In an observational study in patients with hypercalcemia of malignancy, there was no difference between denosumab and IV bisphosphonates in the response rate by day 7 (89 and 86 percent, respectively) [<a href="#rid23">23</a>]. The risk of subsequent hypocalcemia is lower with bisphosphonates than with denosumab.</p><p>For patients in whom bisphosphonates are contraindicated (eg, due to severe kidney impairment, bisphosphonate allergy), or for patients with hypercalcemia refractory to <a class="drug drug_general" data-topicid="9902" href="/d/drug information/9902.html" rel="external">zoledronic acid</a>, <a class="drug drug_general" data-topicid="15575" href="/d/drug information/15575.html" rel="external">denosumab</a> is an option and can be administered concurrently with <a class="drug drug_general" data-topicid="9182" href="/d/drug information/9182.html" rel="external">calcitonin</a> and <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> hydration. (See <a class="local">'Bisphosphonate contraindications or refractory hypercalcemia'</a> below.)</p><p>Our preference for an IV bisphosphonate differs from that of the 2023 Endocrine Society Clinical Practice Guidelines, which suggest <a class="drug drug_general" data-topicid="15575" href="/d/drug information/15575.html" rel="external">denosumab</a> over bisphosphonates for initial therapy of hypercalcemia of malignancy [<a href="#rid24">24</a>]. The Endocrine Society based their suggestion on indirect evidence from randomized trials evaluating outcomes other than hypercalcemia (eg, skeletal-related events, mortality) in patients with cancer and bone metastases but without hypercalcemia [<a href="#rid22">22,25-28</a>]. Osteolytic metastases account for a smaller proportion of cases of hypercalcemia of malignancy than humoral hypercalcemia of malignancy (20 versus almost 80 percent) [<a href="#rid29">29</a>]. (See  <a class="medical medical_review" href="/d/html/842.html" rel="external">"Hypercalcemia of malignancy: Mechanisms", section on 'Mechanisms of hypercalcemia'</a>.) </p><p>Although bisphosphonates are most commonly used to treat established hypercalcemia, they have also been given to prevent hypercalcemia and adverse skeletal events, particularly in patients with metastatic cancer to bone. The use of bisphosphonates to improve outcomes for patients with cancer is discussed separately. (See  <a class="medical medical_review" href="/d/html/2801.html" rel="external">"Osteoclast inhibitors for patients with bone metastases from breast, prostate, and other solid tumors"</a>.)</p><p class="headingAnchor" id="H351528836"><span class="h3">Pretreatment considerations</span><span class="headingEndMark"> — </span>We review vitamin D and creatinine levels prior to administering bisphosphonates. These laboratory tests are usually obtained as part of the evaluation for hypercalcemia. (See  <a class="medical medical_review" href="/d/html/836.html" rel="external">"Diagnostic approach to hypercalcemia", section on 'Laboratory evaluation'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vitamin D</strong> – An elevated serum concentration of 25-hydroxyvitamin D is indicative of vitamin D intoxication due to the ingestion of either vitamin D or calcidiol itself. However, some patients with hypercalcemia due to another etiology (eg, hypercalcemia of malignancy) may have hypercalcemia and concomitant vitamin D <strong>deficiency</strong>. Such patients are more likely to develop hypocalcemia after treatment with <a class="drug drug_general" data-topicid="9902" href="/d/drug information/9902.html" rel="external">zoledronic acid</a> (or <a class="drug drug_general" data-topicid="15575" href="/d/drug information/15575.html" rel="external">denosumab</a>). If the 25-hydroxyvitamin D level is less than 20 ng/dL, vitamin D should be cautiously replaced (eg, 400 to 800 international units daily). (See  <a class="medical medical_review" href="/d/html/2022.html" rel="external">"Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment", section on 'Special populations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Creatinine</strong> – If renal function is impaired, the bisphosphonate should be infused at a slower rate, and in some cases, at a reduced dose. (See <a class="local">'Dosing in renal impairment'</a> below.)</p><p></p><p class="headingAnchor" id="H3003758785"><span class="h3">Choice of drug and dosing</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9902" href="/d/drug information/9902.html" rel="external">Zoledronic acid</a> (4 mg IV over 15 minutes) is preferred over <a class="drug drug_general" data-topicid="9736" href="/d/drug information/9736.html" rel="external">pamidronate</a> (60 to 90 mg over 2 hours) because it is superior to pamidronate in reversing hypercalcemia related to malignancy [<a href="#rid20">20</a>]. <a class="drug drug_general" data-topicid="8887" href="/d/drug information/8887.html" rel="external">Ibandronate</a> and <a class="drug drug_general" data-topicid="8774" href="/d/drug information/8774.html" rel="external">clodronate</a> are less commonly used options. <a class="drug drug_general" data-topicid="9427" href="/d/drug information/9427.html" rel="external">Alendronate</a> and <a class="drug drug_general" data-topicid="10242" href="/d/drug information/10242.html" rel="external">risedronate</a> are potent, third-generation bisphosphonates that can be given orally; however, neither is used for the treatment of severe or acute hypercalcemia.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Zoledronic acid</strong> – In a pooled analysis of two separate phase III trials involving a total of 275 patients with tumor-induced hypercalcemia, a single dose of <a class="drug drug_general" data-topicid="9902" href="/d/drug information/9902.html" rel="external">zoledronic acid</a> (either 4 or 8 mg) normalized the corrected serum calcium concentration in 87 to 88 percent of patients, compared with only 70 percent of those receiving <a class="drug drug_general" data-topicid="9736" href="/d/drug information/9736.html" rel="external">pamidronate</a> (90 mg) [<a href="#rid20">20</a>]. In addition, the median duration of serum calcium control was longer for those receiving zoledronic acid (32 to 43 versus 18 days).</p><p></p><p class="bulletIndent1">Although renal events were reported more frequently with <a class="drug drug_general" data-topicid="9902" href="/d/drug information/9902.html" rel="external">zoledronic acid</a> than with <a class="drug drug_general" data-topicid="9736" href="/d/drug information/9736.html" rel="external">pamidronate</a> in trials evaluating chronic use of these drugs to treat patients with metastatic bone disease, there was no difference in the frequency of grade 3 or 4 renal toxicity with either drug. The efficacy of the 4 and 8 mg zoledronic acid doses were similar, but the 4 mg dose was recommended because there was greater renal toxicity with the 8 mg dose (5.2 versus 2.3 percent with 4 mg) and higher all-cause mortality (33 versus 19 percent) [<a href="#rid30">30</a>]. (See <a class="local">'Dosing in renal impairment'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pamidronate</strong> – A number of observational studies and some randomized trials have demonstrated the efficacy of IV <a class="drug drug_general" data-topicid="9736" href="/d/drug information/9736.html" rel="external">pamidronate</a> for the treatment of hypercalcemia due to excessive bone resorption from a variety of causes, including malignancy, acute primary hyperparathyroidism, immobilization, hypervitaminosis D, and sarcoidosis [<a href="#rid1">1,21,31-40</a>].</p><p></p><p class="bulletIndent1">Early trials showed <a class="drug drug_general" data-topicid="9736" href="/d/drug information/9736.html" rel="external">pamidronate</a> (60 mg over 24 hours) was more effective in ameliorating hypercalcemia of malignancy than IV <a class="drug drug_general" data-topicid="8426" href="/d/drug information/8426.html" rel="external">etidronate</a> (70 versus 41 percent) [<a href="#rid21">21</a>] or <a class="drug drug_general" data-topicid="8774" href="/d/drug information/8774.html" rel="external">clodronate</a> [<a href="#rid37">37</a>]. Subsequent trials showed that shorter infusion times (two to four hours) were safe and effective, maintaining normocalcemia for two or more weeks [<a href="#rid19">19,38</a>].</p><p></p><p class="bulletIndent1">The maximal calcium response occurs at 90 mg IV [<a href="#rid39">39</a>]. However, some clinicians vary the usual initial dose of <a class="drug drug_general" data-topicid="9736" href="/d/drug information/9736.html" rel="external">pamidronate</a> according to the degree of hypercalcemia: 60 mg if the serum calcium concentration is up to 13.5 mg/dL (3 to 3.4 mmol/L) and 90 mg for higher levels. Serum calcium concentrations begin to decrease in one or two days. Doses should not be repeated sooner than a minimum of seven days.</p><p></p><p class="bulletIndent1">IV <a class="drug drug_general" data-topicid="9736" href="/d/drug information/9736.html" rel="external">pamidronate</a> is well tolerated, with a low incidence of fever being the main side effect. A less favorable response may be seen in patients with humoral hypercalcemia of malignancy, a paraneoplastic syndrome typically resulting from autonomous production of parathyroid hormone-related protein (PTHrP) by the tumor [<a href="#rid41">41-43</a>]. Such patients may have a better response to <a class="drug drug_general" data-topicid="9902" href="/d/drug information/9902.html" rel="external">zoledronic acid</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ibandronate</strong> – <a class="drug drug_general" data-topicid="8887" href="/d/drug information/8887.html" rel="external">Ibandronate</a> effectively treats hypercalcemia of malignancy. In combined trials with over 320 patients, ibandronate doses of 2 mg IV administered over two hours normalized serum calcium in up to 67 percent of patients, and doses up to 6 mg were safe and well tolerated [<a href="#rid44">44,45</a>]. The frequency of response was significantly higher with 4 or 6 mg than with 2 mg (76 to 77 versus 50 percent), but the duration of response was not dose dependent [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8887" href="/d/drug information/8887.html" rel="external">Ibandronate</a> appears to be as effective as <a class="drug drug_general" data-topicid="9736" href="/d/drug information/9736.html" rel="external">pamidronate</a>. Ibandronate (2 or 4 mg IV) was directly compared with pamidronate (15 to 90 mg IV) in a randomized trial involving 72 patients with hypercalcemia of malignancy [<a href="#rid46">46</a>]. The number of patients responding to both agents was similar (77 and 76 percent for ibandronate and pamidronate, respectively) but the median time until the serum calcium began to rise again was significantly longer with ibandronate (14 versus 4 days). However, four days is an unusually short duration of effect for pamidronate and may reflect inadequate dosing or the small size of the clinical trial.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clodronate</strong> – <a class="drug drug_general" data-topicid="8774" href="/d/drug information/8774.html" rel="external">Clodronate</a>, a first-generation bisphosphonate, is a relatively weak inhibitor of bone resorption compared with the newer agents. Oral clodronate is available outside the United States. In randomized trials of patients with multiple myeloma or metastatic breast cancer, the administration of oral clodronate to decrease skeletal complications was associated with fewer episodes of severe hypercalcemia. An IV bisphosphonate is often preferred at the onset of therapy, with oral clodronate being used for maintenance therapy. The poor oral bioavailability of clodronate, the size of the tablets, and the need to take them on an empty stomach with nothing to eat for one hour afterward increases the risk of noncompliance [<a href="#rid47">47</a>]. (See  <a class="medical medical_review" href="/d/html/776.html" rel="external">"Use of osteoclast inhibitors in early breast cancer"</a> and  <a class="medical medical_review" href="/d/html/2801.html" rel="external">"Osteoclast inhibitors for patients with bone metastases from breast, prostate, and other solid tumors", section on 'Other bisphosphonates'</a>.)</p><p></p><p class="headingAnchor" id="H608085634"><span class="h3">Side effects and precautions</span><span class="headingEndMark"> — </span>Although IV bisphosphonates are generally well tolerated, side effects may include flu-like symptoms (fever, arthralgias, myalgia, fatigue, bone pain), ocular inflammation (uveitis), hypocalcemia, hypophosphatemia, and impaired renal function, including proteinuria [<a href="#rid48">48-51</a>]. (See <a class="local">'Pretreatment considerations'</a> above.)</p><p>Repetitive use of bisphosphonates has been associated with risk of developing osteonecrosis of the jaw and atypical femur fractures (in patients who require long-term therapy) [<a href="#rid48">48,52</a>]. These side effects associated with long-term therapy may be of limited relevance in the management of acute hypercalcemia where the use of these drugs may be not repeated on a regular basis. Adverse effects of bisphosphonates are reviewed in more detail separately; the incidence varies somewhat with the indication for use, due in part to the higher doses used in cancer patients compared with those with osteoporosis. (See  <a class="medical medical_review" href="/d/html/2806.html" rel="external">"Risks of therapy with bone antiresorptive agents in patients with advanced malignancy"</a> and  <a class="medical medical_review" href="/d/html/104424.html" rel="external">"Risks of bisphosphonate therapy in patients with osteoporosis", section on 'Risks specific to intravenous bisphosphonates'</a> and  <a class="medical medical_review" href="/d/html/104424.html" rel="external">"Risks of bisphosphonate therapy in patients with osteoporosis", section on 'Risks shared by oral and IV bisphosphonates'</a>.)</p><p class="headingAnchor" id="H1867094646"><span class="h3">Dosing in renal impairment</span><span class="headingEndMark"> — </span>In patients with impaired renal function (creatinine &gt;4.5 mg/dL), we suggest caution when using IV bisphosphonates to treat hypercalcemia. Adequate hydration with <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> and treatment with a reduced dose and/or slower infusion rate (2 to 4 mg <a class="drug drug_general" data-topicid="9902" href="/d/drug information/9902.html" rel="external">zoledronic acid</a> over 30 to 60 minutes, 30 to 45 mg <a class="drug drug_general" data-topicid="9736" href="/d/drug information/9736.html" rel="external">pamidronate</a> over 4 hours, 2 mg <a class="drug drug_general" data-topicid="8887" href="/d/drug information/8887.html" rel="external">ibandronate</a> over 1 hour) may minimize risk. The renal tubular toxicity is related to the rate of infusion.</p><p>As mentioned in the preceding section, bisphosphonates have potential nephrotoxicity [<a href="#rid51">51</a>]. However, in clinical trials of <a class="drug drug_general" data-topicid="9902" href="/d/drug information/9902.html" rel="external">zoledronic acid</a> for the treatment of hypercalcemia of malignancy, patients with serum creatinine concentrations as high as 4.5 mg/dL (400 micromol/L) were eligible for participation [<a href="#rid20">20</a>]. In addition, there are case reports of successful use of <a class="drug drug_general" data-topicid="8887" href="/d/drug information/8887.html" rel="external">ibandronate</a> and <a class="drug drug_general" data-topicid="9736" href="/d/drug information/9736.html" rel="external">pamidronate</a> for patients with renal failure and multiple myeloma [<a href="#rid53">53</a>], renal insufficiency (creatinine ≥1.5 mg/dL [133 micromol/L]) [<a href="#rid54">54</a>], and in hemodialysis patients with severe hypercalcemia [<a href="#rid55">55,56</a>].</p><p class="headingAnchor" id="H2461368220"><span class="h2">Bisphosphonate contraindications or refractory hypercalcemia</span><span class="headingEndMark"> — </span>For patients in whom bisphosphonates are contraindicated (eg, due to severe renal impairment, bisphosphonate allergy), or in patients with hypercalcemia refractory to <a class="drug drug_general" data-topicid="9902" href="/d/drug information/9902.html" rel="external">zoledronic acid</a>, <a class="drug drug_general" data-topicid="15575" href="/d/drug information/15575.html" rel="external">denosumab</a> is an option and can be administered concurrently with <a class="drug drug_general" data-topicid="9182" href="/d/drug information/9182.html" rel="external">calcitonin</a> and <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> hydration. (See  <a class="medical medical_review" href="/d/html/2067.html" rel="external">"Denosumab for osteoporosis", section on 'Mechanism of action'</a>.)</p><p>Hemodialysis should be considered in patients who have serum calcium concentrations in the range of 18 to 20 mg/dL (4.5 to 5 mmol/L) and neurologic symptoms but are hemodynamically stable and in those with severe hypercalcemia complicated by renal insufficiency or heart failure, in whom hydration cannot be safely administered [<a href="#rid57">57</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Denosumab</strong><strong> dosing</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Contraindications to bisphosphonates</strong> – For patients in whom bisphosphonates are contraindicated, we treat with an initial dose of 60 mg subcutaneously. Careful monitoring of serum calcium levels is necessary in patients with renal insufficiency because there is a higher risk of hypocalcemia with <a class="drug drug_general" data-topicid="15575" href="/d/drug information/15575.html" rel="external">denosumab</a> than with bisphosphonates [<a href="#rid58">58</a>]. Patients with vitamin D deficiency may be more likely to develop hypocalcemia after denosumab administration. If the serum 25-hydroxyvitamin D returns below normal, we begin cautious treatment with vitamin D (eg, 400 to 800 international units daily). (See <a class="local">'Pretreatment considerations'</a> above.)</p><p></p><p class="bulletIndent2"><a class="drug drug_general" data-topicid="15575" href="/d/drug information/15575.html" rel="external">Denosumab</a>, unlike bisphosphonates, is not cleared by the kidney, and as a consequence, there is no restriction of its use in patients with chronic kidney disease, for whom bisphosphonates are used with caution or contraindicated (see <a class="local">'Dosing in renal impairment'</a> above). In case reports of patients with hypercalcemia of malignancy and severe renal impairment (serum creatinine 2.5 to 5.7 mg/dL), denosumab 60 mg subcutaneously improved serum calcium within two to four days and, in one case, was associated with improvement in renal function [<a href="#rid58">58-60</a>]. Thus, denosumab may have a role in the treatment of hypercalcemia associated with marked renal impairment or renal failure. However, since the renal failure may be due to acute hypercalcemia, avoiding IV bisphosphonates may be unwarranted, especially as denosumab is associated with a higher risk of hypocalcemia than bisphosphonates. (See  <a class="medical medical_review" href="/d/html/2067.html" rel="external">"Denosumab for osteoporosis", section on 'Safety information'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Refractory hypercalcemia</strong> – For patients with hypercalcemia refractory to <a class="drug drug_general" data-topicid="9902" href="/d/drug information/9902.html" rel="external">zoledronic acid</a>, we treat with an initial dose of 120 mg subcutaneously. If after approximately two to seven days there is little improvement, we administer another dose of 120 mg. Thereafter, if the underlying cause of hypercalcemia persists (eg, malignancy), long-term therapy (monthly) is required. (See  <a class="medical medical_review" href="/d/html/2801.html" rel="external">"Osteoclast inhibitors for patients with bone metastases from breast, prostate, and other solid tumors", section on 'Denosumab'</a>.)</p><p></p><p class="bulletIndent2">There are an increasing number of case reports and case series of <a class="drug drug_general" data-topicid="15575" href="/d/drug information/15575.html" rel="external">denosumab</a> for the management of chronic hypercalcemia of malignancy, particularly in patients with persistent hypercalcemia after treatment with bisphosphonates [<a href="#rid59">59,61,62</a>]. In one study, 33 patients with hypercalcemia of malignancy with persistently elevated serum calcium levels corrected for albumin &gt;12.5 mg/dL (3.1 mmol/L) after treatment with bisphosphonates were treated with denosumab 120 mg subcutaneously weekly for three to four weeks and then monthly thereafter. Within 10 days, 21 patients (64 percent) had serum calcium levels &lt;11.5 mg/dL (2.9 mmol/L) [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dialysis</strong> – Hemodialysis with little or no calcium in the dialysis fluid and peritoneal dialysis (though it is slower) are both effective therapies for hypercalcemia and are considered treatments of last resort. Dialysis may be indicated in patients with severe malignancy-associated hypercalcemia and renal insufficiency or heart failure, in whom hydration cannot be safely administered [<a href="#rid64">64</a>].</p><p></p><p class="bulletIndent1">The use of hemodialysis for patients with hypercalcemia but without renal failure may require alterations in the composition of conventional dialysis solutions in order to avoid an exacerbation or induction of other metabolic abnormalities, particularly hypophosphatemia. As an example, hemodialysis with a dialysis solution enriched with phosphorus (final phosphorous concentration of 4 mg/dL) resulted in rapid correction of all abnormalities in one patient in whom medical therapy had failed to reverse hypercalcemia, mental status changes, and hypophosphatemia due to primary hyperparathyroidism [<a href="#rid65">65</a>].</p><p></p><p class="headingAnchor" id="H3683224605"><span class="h1">PREVENTING RECURRENCE</span><span class="headingEndMark"> — </span>Follow-up therapy is aimed at preventing recurrence of hypercalcemia.</p><p class="bulletIndent1"><span class="glyph">●</span>In patients with hypercalcemia of malignancy, progressive hypercalcemia will inevitably accompany tumor progression, and therefore, the underlying disease causing the hypercalcemia should be treated, if at all possible. Many patients with malignancy may also have metastatic bone disease and will receive intravenous (IV) <a class="drug drug_general" data-topicid="9902" href="/d/drug information/9902.html" rel="external">zoledronic acid</a> or <a class="drug drug_general" data-topicid="9736" href="/d/drug information/9736.html" rel="external">pamidronate</a> every three to four weeks as part of their treatment to prevent skeletal complications. As a result, recurrent hypercalcemia will be prevented. (See  <a class="medical medical_review" href="/d/html/2801.html" rel="external">"Osteoclast inhibitors for patients with bone metastases from breast, prostate, and other solid tumors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with renal insufficiency and history of hypercalcemia, calcium intake should be limited to 1000 mg per day (total diet plus any supplements). Excessive vitamin D supplements (<a class="drug drug_general" data-topicid="10150" href="/d/drug information/10150.html" rel="external">ergocalciferol</a> or <a class="drug drug_general" data-topicid="10117" href="/d/drug information/10117.html" rel="external">cholecalciferol</a>) should be avoided. (See  <a class="medical medical_review" href="/d/html/1964.html" rel="external">"Management of secondary hyperparathyroidism in adult nondialysis patients with chronic kidney disease", section on 'Initial treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with normal renal function and history of hypercalcemia, excessive amounts of calcium and vitamin D supplements should also be avoided.</p><p></p><p class="headingAnchor" id="H1248559"><span class="h1">DISEASE-SPECIFIC APPROACH</span><span class="headingEndMark"> — </span>The modalities described above apply in varying degrees to patients with all causes of hypercalcemia. The treatment of specific disorders is discussed in detail in other topic reviews. Summarized briefly:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hyperparathyroidism</strong> – Hyperparathyroidism is the most common outpatient cause of mild hypercalcemia. The treatment is typically parathyroidectomy or monitoring for complications of primary hyperparathyroidism. (See  <a class="medical medical_review" href="/d/html/2065.html" rel="external">"Primary hyperparathyroidism: Management"</a>.)</p><p></p><p class="bulletIndent1">Parathyroid carcinoma is a rare cause of hyperparathyroidism but may cause more severe hypercalcemia than most parathyroid adenomas. Patients typically present with marked hypercalcemia and very high parathyroid hormone concentrations or a neck mass. The primary treatment of parathyroid carcinoma is surgery. When the tumor is no longer curable by surgical intervention, treatment becomes focused on the control of hypercalcemia with medical therapy, which can include bisphosphonates, calcimimetic agents, or <a class="drug drug_general" data-topicid="15575" href="/d/drug information/15575.html" rel="external">denosumab</a>. (See  <a class="medical medical_review" href="/d/html/2042.html" rel="external">"Parathyroid carcinoma", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1">The calcimimetic agent <a class="drug drug_general" data-topicid="8850" href="/d/drug information/8850.html" rel="external">cinacalcet</a> reduces the serum calcium concentration in patients with severe hypercalcemia due to parathyroid carcinoma and in hemodialysis patients with an elevated calcium-phosphorous product and secondary hyperparathyroidism. Calcimimetics have also been evaluated in patients with primary hyperparathyroidism but are not standard therapy. (See  <a class="medical medical_review" href="/d/html/2042.html" rel="external">"Parathyroid carcinoma", section on 'Treatment'</a> and  <a class="medical medical_review" href="/d/html/2065.html" rel="external">"Primary hyperparathyroidism: Management", section on 'Severe hypercalcemia'</a> and  <a class="medical medical_review" href="/d/html/1918.html" rel="external">"Management of secondary hyperparathyroidism in adult patients on dialysis", section on 'Calcimimetics'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Granulomatous diseases</strong> – Patients with lymphoma, sarcoidosis, or other granulomatous causes of hypercalcemia have enhanced intestinal calcium absorption due to increased endogenous calcitriol production. The major modalities of therapy are a low-calcium diet, glucocorticoids, and treatment of the underlying disease. Glucocorticoids (eg, <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> in a dose of 20 to 40 mg/day) will usually reduce serum calcium concentrations within two to five days by decreasing calcitriol production by the activated mononuclear cells in the lung and lymph nodes and by reducing intestinal calcium absorption. (See  <a class="medical medical_review" href="/d/html/841.html" rel="external">"Hypercalcemia in granulomatous diseases"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypervitaminosis D</strong> – Hypercalcemia associated with excess administration or ingestion of vitamin D is primarily due to increased absorption of dietary calcium. It is sometimes seen in combination with excess calcium intake and in individuals with renal insufficiency. High doses of vitamin D also have been shown to increase bone resorption, by activating osteoclasts. Vitamin D actions on the distal nephron will increase the tubular reabsorption of calcium, which further worsens hypercalcemia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Calcitriol</strong> – Hypercalcemia due to ingestion of calcitriol as treatment for hypoparathyroidism, or for the hypocalcemia and hyperparathyroidism of renal failure, usually lasts only one to two days because of the relatively short biologic half-life of calcitriol. Thus, stopping the calcitriol, increasing salt and fluid intake, or perhaps hydrating with intravenous (IV) <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> may be the only therapy that is needed.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Vitamin D</strong> – Hypercalcemia caused by vitamin D or calcidiol lasts longer, so that more aggressive therapy such as glucocorticoids (eg, <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> in a dose of 20 to 40 mg/day) and <a class="drug drug_general" data-topicid="9902" href="/d/drug information/9902.html" rel="external">zoledronic acid</a> or <a class="drug drug_general" data-topicid="9736" href="/d/drug information/9736.html" rel="external">pamidronate</a> may be necessary [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Familial hypocalciuric hypercalcemia</strong> – Hypercalcemia is typically not treated in patients with familial hypocalciuric hypercalcemia (FHH), because the elevation in serum calcium is typically mild and produces few, if any, symptoms. (See  <a class="medical medical_review" href="/d/html/838.html" rel="external">"Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia"</a>.)</p><p></p><p class="headingAnchor" id="H23"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong> – The degree of hypercalcemia, along with the rate of rise of serum calcium concentration, often determines symptoms and the urgency of therapy. The therapeutic approach should reflect these differences. (See <a class="local">'Preferred approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mild hypercalcemia</strong> – Patients with asymptomatic or mildly symptomatic hypercalcemia (calcium &lt;12 mg/dL [3 mmol/L]) do not require immediate treatment. However, they should be advised to avoid factors that can aggravate hypercalcemia, including thiazide diuretics and <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> carbonate therapy, volume depletion, prolonged bed rest or inactivity, calcium and/or vitamin D supplements, and a high-calcium diet (&gt;1000 mg/day). (See <a class="local">'Mild hypercalcemia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Moderate hypercalcemia</strong> – Asymptomatic or mildly symptomatic individuals with chronic moderate hypercalcemia (calcium between 12 and 14 mg/dL [3 to 3.5 mmol/L]) may not require immediate therapy. However, an acute rise to these levels may cause changes in sensorium, which requires treatment as described for severe hypercalcemia. (See <a class="local">'Moderate hypercalcemia'</a> above and <a class="local">'Severe hypercalcemia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe hypercalcemia</strong> – Patients with more severe (calcium &gt;14 mg/dL [3.5 mmol/L]) or symptomatic (eg, lethargy, stupor) hypercalcemia require aggressive therapy. Initial therapy of severe hypercalcemia includes the simultaneous administration of intravenous (IV) isotonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>, subcutaneous <a class="drug drug_general" data-topicid="9182" href="/d/drug information/9182.html" rel="external">calcitonin</a>, and a bisphosphonate (typically, IV <a class="drug drug_general" data-topicid="9902" href="/d/drug information/9902.html" rel="external">zoledronic acid</a>)  (<a class="graphic graphic_table graphicRef73030" href="/d/graphic/73030.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Isotonic </strong><strong>saline</strong> – Most patients with severe hypercalcemia have marked intravascular volume depletion. Isotonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> for 24 to 48 hours corrects volume depletion and enhances renal excretion of calcium. A reasonable initial rate is 200 to 300 mL/hour that is then adjusted to maintain the urine output at 100 to 150 mL/hour. We suggest <strong>not</strong> routinely using a loop diuretic (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). However, in individuals with renal insufficiency or heart failure, careful monitoring and judicious use of loop diuretics (after intravascular volume has been repleted) may be required to prevent fluid overload. (See <a class="local">'Severe hypercalcemia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Calcitonin</strong> – For immediate, short-term management of hypercalcemia in symptomatic patients (eg, lethargy, stupor) with calcium &gt;14 mg/dL (3.5 mmol/L), we suggest administration of <a class="drug drug_general" data-topicid="9182" href="/d/drug information/9182.html" rel="external">calcitonin</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Calcitonin is used in combination with <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> hydration and bisphosphonates. The initial dose is 4 units/kg, administered subcutaneously or intramuscularly. (See <a class="local">'Severe hypercalcemia'</a> above and <a class="local">'Calcitonin'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bisphosphonates</strong> – For longer-term control of hypercalcemia in patients with more severe (calcium &gt;14 mg/dL) or symptomatic hypercalcemia due to excessive bone resorption, we suggest the addition of an IV bisphosphonate rather than <a class="drug drug_general" data-topicid="15575" href="/d/drug information/15575.html" rel="external">denosumab</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Bisphosphonates have a long track record of safety and randomized trial evidence of efficacy for the treatment of hypercalcemia due to excessive bone resorption from a variety of causes, including malignancy-related hypercalcemia. (See <a class="local">'Severe hypercalcemia'</a> above and <a class="local">'Choice of antiresorptive agent: Bisphosphonates'</a> above.)</p><p></p><p class="bulletIndent2">Among IV bisphosphonates, we suggest <a class="drug drug_general" data-topicid="9902" href="/d/drug information/9902.html" rel="external">zoledronic acid</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). The initial dose is 4 mg IV over 15 minutes. (See <a class="local">'Choice of drug and dosing'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Refractory hypercalcemia or bisphosphonate contraindications</strong> – <a class="drug drug_general" data-topicid="15575" href="/d/drug information/15575.html" rel="external">Denosumab</a> is an option for patients with hypercalcemia that is refractory to <a class="drug drug_general" data-topicid="9902" href="/d/drug information/9902.html" rel="external">zoledronic acid</a> or in whom bisphosphonates are contraindicated due to severe renal impairment or bisphosphonate allergy. Careful monitoring of serum calcium levels is necessary in patients with renal impairment because there is a higher risk of hypocalcemia with denosumab than with bisphosphonates. Dialysis may be indicated in patients with severe malignancy-associated hypercalcemia and renal insufficiency or heart failure, in whom hydration cannot be safely administered. (See <a class="local">'Bisphosphonate contraindications or refractory hypercalcemia'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bilezikian JP. Clinical review 51: Management of hypercalcemia. J Clin Endocrinol Metab 1993; 77:1445.</a></li><li><a class="nounderline abstract_t">Bilezikian JP. Management of acute hypercalcemia. N Engl J Med 1992; 326:1196.</a></li><li><a class="nounderline abstract_t">Maier JD, Levine SN. Hypercalcemia in the Intensive Care Unit: A Review of Pathophysiology, Diagnosis, and Modern Therapy. J Intensive Care Med 2015; 30:235.</a></li><li><a class="nounderline abstract_t">Carroll MF, Schade DS. A practical approach to hypercalcemia. Am Fam Physician 2003; 67:1959.</a></li><li><a class="nounderline abstract_t">Fatemi S, Singer FR, Rude RK. Effect of salmon calcitonin and etidronate on hypercalcemia of malignancy. Calcif Tissue Int 1992; 50:107.</a></li><li><a class="nounderline abstract_t">Hosking DJ, Cowley A, Bucknall CA. Rehydration in the treatment of severe hypercalcaemia. Q J Med 1981; 50:473.</a></li><li><a class="nounderline abstract_t">Khoury N, Carmichael KA. Evaluation and therapy of hypercalcemia. Mo Med 2011; 108:99.</a></li><li><a class="nounderline abstract_t">Makras P, Papapoulos SE. Medical treatment of hypercalcaemia. Hormones (Athens) 2009; 8:83.</a></li><li><a class="nounderline abstract_t">LeGrand SB, Leskuski D, Zama I. Narrative review: furosemide for hypercalcemia: an unproven yet common practice. Ann Intern Med 2008; 149:259.</a></li><li><a class="nounderline abstract_t">Dumon JC, Magritte A, Body JJ. Nasal human calcitonin for tumor-induced hypercalcemia. Calcif Tissue Int 1992; 51:18.</a></li><li><a class="nounderline abstract_t">Deftos LJ, First BP. Calcitonin as a drug. Ann Intern Med 1981; 95:192.</a></li><li><a class="nounderline abstract_t">Ljunghall S. Use of clodronate and calcitonin in hypercalcemia due to malignancy. Recent Results Cancer Res 1989; 116:40.</a></li><li><a class="nounderline abstract_t">Chevallier B, Peyron R, Basuyau JP, et al. [Human calcitonin in neoplastic hypercalcemia. Results of a prospective randomized trial]. Presse Med 1988; 17:2375.</a></li><li><a class="nounderline abstract_t">Austin LA, Heath H 3rd. Calcitonin: physiology and pathophysiology. N Engl J Med 1981; 304:269.</a></li><li><a class="nounderline abstract_t">Wisneski LA. Salmon calcitonin in the acute management of hypercalcemia. Calcif Tissue Int 1990; 46 Suppl:S26.</a></li><li><a class="nounderline abstract_t">Vaughn CB, Vaitkevicius VK. The effects of calcitonin in hypercalcemia in patients with malignancy. Cancer 1974; 34:1268.</a></li><li><a class="nounderline abstract_t">Minisola S, Pepe J, Piemonte S, Cipriani C. The diagnosis and management of hypercalcaemia. BMJ 2015; 350:h2723.</a></li><li><a class="nounderline abstract_t">Singer FR, Ritch PS, Lad TE, et al. Treatment of hypercalcemia of malignancy with intravenous etidronate. A controlled, multicenter study. The Hypercalcemia Study Group. Arch Intern Med 1991; 151:471.</a></li><li><a class="nounderline abstract_t">Gucalp R, Theriault R, Gill I, et al. Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone. Arch Intern Med 1994; 154:1935.</a></li><li><a class="nounderline abstract_t">Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001; 19:558.</a></li><li><a class="nounderline abstract_t">Gucalp R, Ritch P, Wiernik PH, et al. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. J Clin Oncol 1992; 10:134.</a></li><li><a class="nounderline abstract_t">Seisa MO, Nayfeh T, Hasan B, et al. A Systematic Review Supporting the Endocrine Society Clinical Practice Guideline on the Treatment of Hypercalcemia of Malignancy in Adults. J Clin Endocrinol Metab 2023; 108:585.</a></li><li><a class="nounderline abstract_t">Lei MM, Tavares E, Buzgo E, et al. Denosumab versus intravenous bisphosphonate use for hypercalcemia in multiple myeloma. Leuk Lymphoma 2022; 63:3249.</a></li><li><a class="nounderline abstract_t">El-Hajj Fuleihan G, Clines GA, Hu MI, et al. Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2023; 108:507.</a></li><li><a class="nounderline abstract_t">Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010; 28:5132.</a></li><li><a class="nounderline abstract_t">Scagliotti GV, Hirsh V, Siena S, et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol 2012; 7:1823.</a></li><li><a class="nounderline abstract_t">Lipton A, Fizazi K, Stopeck AT, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 2012; 48:3082.</a></li><li><a class="nounderline abstract_t">Bassatne A, Murad MH, Piggott T, et al. Patient and Physician Decisional Factors Regarding Hypercalcemia of Malignancy Treatment: A Novel Mixed-Methods Study. J Clin Endocrinol Metab 2023; 108:563.</a></li><li class="breakAll">Horwitz MJ. Non-parathyroid hypercalcemia. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 9th ed, Bilezikian JP (Ed), Wiley-Blackwell, Hoboken, NJ 2018. p.639.</li><li><a class="nounderline abstract_t">Schwartz LM, Woloshin S. Lost in transmission--FDA drug information that never reaches clinicians. N Engl J Med 2009; 361:1717.</a></li><li><a class="nounderline abstract_t">Massagli TL, Cardenas DD. Immobilization hypercalcemia treatment with pamidronate disodium after spinal cord injury. Arch Phys Med Rehabil 1999; 80:998.</a></li><li><a class="nounderline abstract_t">Jansson S, Tisell LE, Lindstedt G, Lundberg PA. Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism. Surgery 1991; 110:480.</a></li><li><a class="nounderline abstract_t">Mark S. Hypercalcaemia in an immobilised patient with pneumonia. Br J Clin Pract 1995; 49:327.</a></li><li><a class="nounderline abstract_t">McIntyre HD, Cameron DP, Urquhart SM, Davies WE. Immobilization hypercalcaemia responding to intravenous pamidronate sodium therapy. Postgrad Med J 1989; 65:244.</a></li><li><a class="nounderline abstract_t">Selby PL, Davies M, Marks JS, Mawer EB. Vitamin D intoxication causes hypercalcaemia by increased bone resorption which responds to pamidronate. Clin Endocrinol (Oxf) 1995; 43:531.</a></li><li><a class="nounderline abstract_t">Gibbs CJ, Peacock M. Hypercalcaemia due to sarcoidosis corrects with bisphosphonate treatment. Postgrad Med J 1986; 62:937.</a></li><li><a class="nounderline abstract_t">Ralston SH, Gallacher SJ, Patel U, et al. Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia. Lancet 1989; 2:1180.</a></li><li><a class="nounderline abstract_t">Sawyer N, Newstead C, Drummond A, Cunningham J. Fast (4-h) or slow (24-h) infusions of pamidronate disodium (aminohydroxypropylidene diphosphonate (APD)) as single shot treatment of hypercalcaemia. Bone Miner 1990; 9:121.</a></li><li><a class="nounderline abstract_t">Nussbaum SR, Younger J, Vandepol CJ, et al. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. Am J Med 1993; 95:297.</a></li><li><a class="nounderline abstract_t">Wimalawansa SJ. Optimal frequency of administration of pamidronate in patients with hypercalcaemia of malignancy. Clin Endocrinol (Oxf) 1994; 41:591.</a></li><li><a class="nounderline abstract_t">Gurney H, Grill V, Martin TJ. Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia. Lancet 1993; 341:1611.</a></li><li><a class="nounderline abstract_t">Walls J, Ratcliffe WA, Howell A, Bundred NJ. Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein. Br J Cancer 1994; 70:169.</a></li><li><a class="nounderline abstract_t">Wimalawansa SJ. Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate. Cancer 1994; 73:2223.</a></li><li><a class="nounderline abstract_t">Ralston SH, Thiébaud D, Herrmann Z, et al. Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia. Br J Cancer 1997; 75:295.</a></li><li><a class="nounderline abstract_t">Pecherstorfer M, Herrmann Z, Body JJ, et al. Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. J Clin Oncol 1996; 14:268.</a></li><li><a class="nounderline abstract_t">Pecherstorfer M, Steinhauer EU, Rizzoli R, et al. Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate. Support Care Cancer 2003; 11:539.</a></li><li><a class="nounderline abstract_t">Berenson JR. Treatment of hypercalcemia of malignancy with bisphosphonates. Semin Oncol 2002; 29:12.</a></li><li><a class="nounderline abstract_t">Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 2006; 17:897.</a></li><li><a class="nounderline abstract_t">Zojer N, Keck AV, Pecherstorfer M. Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf 1999; 21:389.</a></li><li><a class="nounderline abstract_t">Rahbari-Oskoui F, Fielder O, Ghasemzadeh N, Hennigar R. Prolonged recovery time from zoledronic Acid induced acute tubular necrosis: a case report and review of the literature. Case Rep Nephrol 2013; 2013:651246.</a></li><li><a class="nounderline abstract_t">Palmer S, Tillman F 3rd, Sharma P, et al. Safety of Intravenous Bisphosphonates for the Treatment of Hypercalcemia in Patients With Preexisting Renal Dysfunction. Ann Pharmacother 2021; 55:303.</a></li><li><a class="nounderline abstract_t">Edwards BJ, Sun M, West DP, et al. Incidence of Atypical Femur Fractures in Cancer Patients: The MD Anderson Cancer Center Experience. J Bone Miner Res 2016; 31:1569.</a></li><li><a class="nounderline abstract_t">Henrich D, Hoffmann M, Uppenkamp M, Bergner R. Ibandronate for the treatment of hypercalcemia or nephrocalcinosis in patients with multiple myeloma and acute renal failure: Case reports. Acta Haematol 2006; 116:165.</a></li><li><a class="nounderline abstract_t">Machado CE, Flombaum CD. Safety of pamidronate in patients with renal failure and hypercalcemia. Clin Nephrol 1996; 45:175.</a></li><li><a class="nounderline abstract_t">Trimarchi H, Lombi F, Forrester M, et al. Disodium pamidronate for treating severe hypercalcemia in a hemodialysis patient. Nat Clin Pract Nephrol 2006; 2:459.</a></li><li><a class="nounderline abstract_t">Davenport A, Goel S, Mackenzie JC. Treatment of hypercalcaemia with pamidronate in patients with end stage renal failure. Scand J Urol Nephrol 1993; 27:447.</a></li><li><a class="nounderline abstract_t">Walker MD, Shane E. Hypercalcemia: A Review. JAMA 2022; 328:1624.</a></li><li><a class="nounderline abstract_t">Cicci JD, Buie L, Bates J, van Deventer H. Denosumab for the management of hypercalcemia of malignancy in patients with multiple myeloma and renal dysfunction. Clin Lymphoma Myeloma Leuk 2014; 14:e207.</a></li><li><a class="nounderline abstract_t">Dietzek A, Connelly K, Cotugno M, et al. Denosumab in hypercalcemia of malignancy: a case series. J Oncol Pharm Pract 2015; 21:143.</a></li><li><a class="nounderline abstract_t">Bech A, de Boer H. Denosumab for tumor-induced hypercalcemia complicated by renal failure. Ann Intern Med 2012; 156:906.</a></li><li><a class="nounderline abstract_t">Karuppiah D, Thanabalasingham G, Shine B, et al. Refractory hypercalcaemia secondary to parathyroid carcinoma: response to high-dose denosumab. Eur J Endocrinol 2014; 171:K1.</a></li><li><a class="nounderline abstract_t">Adhikaree J, Newby Y, Sundar S. Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy. BMJ Case Rep 2014; 2014.</a></li><li><a class="nounderline abstract_t">Hu MI, Glezerman IG, Leboulleux S, et al. Denosumab for treatment of hypercalcemia of malignancy. J Clin Endocrinol Metab 2014; 99:3144.</a></li><li><a class="nounderline abstract_t">Koo WS, Jeon DS, Ahn SJ, et al. Calcium-free hemodialysis for the management of hypercalcemia. Nephron 1996; 72:424.</a></li><li><a class="nounderline abstract_t">Leehey DJ, Ing TS. Correction of hypercalcemia and hypophosphatemia by hemodialysis using a conventional, calcium-containing dialysis solution enriched with phosphorus. Am J Kidney Dis 1997; 29:288.</a></li></ol></div><div id="topicVersionRevision">Topic 850 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8263125" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical review 51: Management of hypercalcemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1532633" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Management of acute hypercalcemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24130250" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Hypercalcemia in the Intensive Care Unit: A Review of Pathophysiology, Diagnosis, and Modern Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12751658" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : A practical approach to hypercalcemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1571826" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Effect of salmon calcitonin and etidronate on hypercalcemia of malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7342172" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Rehydration in the treatment of severe hypercalcaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21568230" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Evaluation and therapy of hypercalcemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19570736" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Medical treatment of hypercalcaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18711156" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Narrative review: furosemide for hypercalcemia: an unproven yet common practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1393770" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Nasal human calcitonin for tumor-induced hypercalcemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7258871" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Calcitonin as a drug.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2527399" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Use of clodronate and calcitonin in hypercalcemia due to malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2974978" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : [Human calcitonin in neoplastic hypercalcemia. Results of a prospective randomized trial].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7003392" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Calcitonin: physiology and pathophysiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2137363" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Salmon calcitonin in the acute management of hypercalcemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4472732" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The effects of calcitonin in hypercalcemia in patients with malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26037642" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The diagnosis and management of hypercalcaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1900410" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Treatment of hypercalcemia of malignancy with intravenous etidronate. A controlled, multicenter study. The Hypercalcemia Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8074597" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11208851" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1727915" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36545700" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A Systematic Review Supporting the Endocrine Society Clinical Practice Guideline on the Treatment of Hypercalcemia of Malignancy in Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36036363" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Denosumab versus intravenous bisphosphonate use for hypercalcemia in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36545746" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21060033" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23154554" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22975218" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36545699" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Patient and Physician Decisional Factors Regarding Hypercalcemia of Malignancy Treatment: A Novel Mixed-Methods Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36545699" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Patient and Physician Decisional Factors Regarding Hypercalcemia of Malignancy Treatment: A Novel Mixed-Methods Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19846841" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Lost in transmission--FDA drug information that never reaches clinicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10488998" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Immobilization hypercalcemia treatment with pamidronate disodium after spinal cord injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1845370" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8554961" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Hypercalcaemia in an immobilised patient with pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2594602" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Immobilization hypercalcaemia responding to intravenous pamidronate sodium therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8548936" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Vitamin D intoxication causes hypercalcaemia by increased bone resorption which responds to pamidronate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3774726" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Hypercalcaemia due to sarcoidosis corrects with bisphosphonate treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2572902" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2350615" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Fast (4-h) or slow (24-h) infusions of pamidronate disodium (aminohydroxypropylidene diphosphonate (APD)) as single shot treatment of hypercalcaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8368227" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7828347" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Optimal frequency of administration of pamidronate in patients with hypercalcaemia of malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8099988" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8018531" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8156530" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9010041" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8558208" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12783289" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12584690" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Treatment of hypercalcemia of malignancy with bisphosphonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16547070" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Management of the adverse effects associated with intravenous bisphosphonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10554053" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Comparative tolerability of drug therapies for hypercalcaemia of malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24527249" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Prolonged recovery time from zoledronic Acid induced acute tubular necrosis: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32847379" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Safety of Intravenous Bisphosphonates for the Treatment of Hypercalcemia in Patients With Preexisting Renal Dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26896384" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Incidence of Atypical Femur Fractures in Cancer Patients: The MD Anderson Cancer Center Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17016034" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Ibandronate for the treatment of hypercalcemia or nephrocalcinosis in patients with multiple myeloma and acute renal failure: Case reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8706358" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Safety of pamidronate in patients with renal failure and hypercalcemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16932480" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Disodium pamidronate for treating severe hypercalcemia in a hemodialysis patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8159916" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Treatment of hypercalcaemia with pamidronate in patients with end stage renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36282253" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Hypercalcemia: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25128013" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Denosumab for the management of hypercalcemia of malignancy in patients with multiple myeloma and renal dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24415364" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Denosumab in hypercalcemia of malignancy: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22711097" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Denosumab for tumor-induced hypercalcemia complicated by renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24743399" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Refractory hypercalcaemia secondary to parathyroid carcinoma: response to high-dose denosumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24481018" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24915117" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Denosumab for treatment of hypercalcemia of malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8852491" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Calcium-free hemodialysis for the management of hypercalcemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9016904" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Correction of hypercalcemia and hypophosphatemia by hemodialysis using a conventional, calcium-containing dialysis solution enriched with phosphorus.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
